SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001337553-22-000039
Filing Date
2022-11-03
Accepted
2022-11-03 16:07:20
Documents
14
Period of Report
2022-11-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aeri-20221101.htm   iXBRL 8-K 45042
2 EX-99.1 aeri-3q22earningsreleaseex.htm EX-99.1 182059
6 aerielogo.jpg GRAPHIC 8185
  Complete submission text file 0001337553-22-000039.txt   389401

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aeri-20221101.xsd EX-101.SCH 1924
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aeri-20221101_lab.xml EX-101.LAB 24137
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aeri-20221101_pre.xml EX-101.PRE 12526
8 EXTRACTED XBRL INSTANCE DOCUMENT aeri-20221101_htm.xml XML 10728
Mailing Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703
Business Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703 (919) 237-5300
AERIE PHARMACEUTICALS INC (Filer) CIK: 0001337553 (see all company filings)

IRS No.: 203109565 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36152 | Film No.: 221357969
SIC: 2836 Biological Products, (No Diagnostic Substances)